TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
Study: NCT03697161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 (gaboxadol)
Description: OV101 (gaboxadol)
Study: NCT04263116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Assisted Maturation
Description: Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
Study: NCT03255304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: palatability mindset
Description: groups be confronted with palatability aspects of food items
Study: NCT01907776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME1100 inhalation solution
Description: ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
Study: NCT01907776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ME1100 placebo inhalation solution
Description: Vehicle placebo
Study: NCT00841269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uridine
Description: Uridine 500 mg by mouth twice per day for 6 weeks
Study: NCT03846167

Intervention type: DRUG
Intervention: Imaging Drug FluorThanatrace (FTT)
Description: \[18F\]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
Study: NCT02715492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: (Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Trans arterial chemoembolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Trans arterial chemoembolization
Study: NCT01092026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cord blood transplantation
Description: One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
Study: NCT03127579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Longer meal duration
Description: Participants have 50% more time to eat than usual
Study: NCT02206321

Intervention type: PROCEDURE
Intervention: Navigation total knee arthroplasty
Description: computer assisted navigation total knee arthroplasty without femur intramedullary involvement

Intervention type: PROCEDURE
Intervention: Conventional total knee arthroplasty
Description: conventional technique with femur intramedullary violation
Study: NCT00083551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
Study: NCT01192841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician uniform
Description: Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
Study: NCT01920438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy
Description: PEG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologically-guided insertion of Gastrostomy
Description: RIG
Study: NCT00640146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Study: NCT00083551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant GM-CSF
Description: GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant GM-CSF
Description: GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha-2b
Description: AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha-2b
Description: AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
Study: NCT02104791

Intervention type: DRUG
Intervention: procalcitonin
Description: In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?

Intervention type: DRUG
Intervention: procalcitonin
Description: In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?

Intervention type: DRUG
Intervention: procalcitonin
Description: In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
Study: NCT01488461

Intervention type: GENETIC
Intervention: blood sample
Description: Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
Study: NCT01844297

Intervention type: DRUG
Group type: OTHER
Intervention: TDF+3TC+EFV
Study: NCT03666520

Intervention type: OTHER
Intervention: Clinical Decision Support prompted to the clinician to convert drug.
Description: This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
Study: NCT02455804

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenting procedure
Description: All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
Study: NCT04661111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hymovis® ONE (32 mg/4 ml)
Description: Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
Study: NCT01057693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as capsules and given 3 times daily.
Study: NCT02413996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetec® knee continuous passive motion (CPM )
Description: CPM of the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinetec® knee continuous passive motion (CPM )
Description: CPM of the knee

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional activities
Description: Stairs, walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional activities
Description: Stairs, walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRRS rehabilitation
Description: exercise therapy through a virtual reality rehabilitation system (VRRS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: exercise therapy through a traditional rehabilitation training made by physiotherapists
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
Study: NCT01148472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20mg once daily; orally
Study: NCT01972724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed in clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed in clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed in clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea as prescribed in clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea as prescribed in clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea as prescribed in clinical practice
Study: NCT00640146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Study: NCT01485432

Intervention type: DEVICE
Intervention: PiCCO® Monitoring
Description: Fluid and vasopressor management according to PiCCO measurements
Study: NCT02046382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Study: NCT02966613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMK Medacta Total Knee arthroplasty
Description: Total Knee arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMK Medacta Total Knee arthroplasty
Description: Total Knee arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMK Medacta Total Knee arthroplasty
Description: Total Knee arthroplasty
Study: NCT02564744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1562
Description: Administered as IV Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1562
Description: Administered as IV Infusion.
Study: NCT00712933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.
Study: NCT01280019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment manoeuvre
Description: Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar recruitment manoeuvre
Description: Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
Study: NCT01808404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Guided Self-Help
Description: The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness.
Study: NCT01736423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral
Study: NCT02526212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G-BMT
Description: The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
Study: NCT01148472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60mg once daily; orally
Study: NCT02469298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 (Danirixin)
Description: It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 (Danirixin)
Description: It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo To Match GSK1325756
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo To Match GSK1325756
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
Study: NCT04443842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and social incentives
Description: Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
Study: NCT02469298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo To Match Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo To Match Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
Study: NCT00814307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5mg CP-690,550 BID PO for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg CP-690,550 BID PO for 6 months
Study: NCT02564744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1562
Description: Administered as IV Infusion.
Study: NCT00814307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
Study: NCT02526212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: All participants will continue to receive maintenance treatment with buprenorphine-naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All participants will continue to receive maintenance treatment with buprenorphine-naloxone
Study: NCT04741321

Intervention type: OTHER
Intervention: VascuQol-6 questionnaire Spanish version
Description: VascuQol-6 questionnaire was translated by two professional translators into Spanish.

Intervention type: OTHER
Intervention: VascuQol-6 questionnaire Spanish version
Description: VascuQol-6 questionnaire was translated by two professional translators into Spanish.
Study: NCT03338478

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
Study: NCT05802511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: Exablate treatment for Neuropathic Pain
Study: NCT00646113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX 3.0S
Description: OsseoSpeed™ TX 3.0 mm diameter
Study: NCT03182621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK
Description: The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
Study: NCT01390298

Intervention type: OTHER
Intervention: Observational
Description: Observational study only
Study: NCT00517816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)
Study: NCT03182621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARK
Description: traditional YMCA program
Study: NCT00004467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 5% dextrose
Study: NCT04916756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: baricitinib 2mg per day for 24 weeks